Enovis (NYSE:ENOV) Stock Rating Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other brokerages also recently commented on ENOV. BTIG Research reduced their price target on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, September 1st. Weiss Ratings lowered Enovis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. UBS Group restated a “buy” rating and set a $44.00 price objective on shares of Enovis in a report on Monday, October 5th. Evercore set a $32.00 target price on Enovis in a research report on Monday, July 6th. Finally, BMO Capital Markets set a $27.00 target price on Enovis in a research note on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Enovis Stock Performance

Enovis stock opened at $19.92 on Friday. Enovis has a 12-month low of $16.70 and a 12-month high of $32.41. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -1.03 and a beta of 1.37. The firm’s fifty day moving average price is $20.02 and its 200 day moving average price is $23.08.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis will post 3.15 EPS for the current fiscal year.

Insider Activity

In related news, insider Oliver Engert bought 2,660 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $18.80 per share, with a total value of $50,008.00. Following the transaction, the insider owned 63,898 shares of the company’s stock, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Damien Mcdonald bought 13,035 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 23,293 shares of company stock valued at $449,599 in the last three months. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Paradigm Capital Management Inc. NY acquired a new position in Enovis in the second quarter worth $28,533,000. Bank of America Corp DE bought a new stake in Enovis during the second quarter valued at $11,502,000. Man Group plc bought a new stake in Enovis during the second quarter valued at $8,711,000. Front Street Capital Management Inc. increased its stake in Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares during the last quarter. Finally, Private Management Group Inc. raised its holdings in shares of Enovis by 38.8% during the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock worth $28,257,000 after purchasing an additional 381,705 shares during the period. 98.45% of the stock is owned by institutional investors.

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.